NOVN enters the week down 8% over the past month, closing Tuesday at CHF 113.54. The most striking tension here is the gap between insider behaviour — persistent and sizeable selling — and an analyst community that sees nearly 37% upside to a mean target of CHF 154.95.
Insider activity has been a consistent one-way trade. In the 90 days to end-March, undisclosed executives and a board member filed net disposals totalling roughly $42 million in value — all sells, no purchases. The largest individual transactions came on 6 February, when an executive committee member offloaded more than 110,000 shares across two filings worth nearly $17 million combined. A non-executive director then added another $11 million in sales at the end of March. The frequency and scale of the selling is notable against a stock that has already lost ground in 2026.
The short-selling picture, by contrast, tells a very different story. Short interest has collapsed since mid-March, falling from a peak near 1.1% of the free float in the third week of March to just 0.15% at last count — the lowest reading in the dataset. That's not a modest retracement; it's an almost complete unwind of a positioning built over weeks, with roughly 17 million shares covered in about five weeks. The ORTEX short score at 26.3 — ranking in the 94th percentile for low short pressure — confirms there is no meaningful short-side thesis left in the market. Borrow costs remain negligible at 0.71% APR, and the lending pool is extremely loose, with very little of available supply currently in use relative to the 52-week maximum. Short sellers have exited; they are not the story here.
The Street remains firmly constructive, with analyst recommendation divergence ranking in the 97th percentile — implying the consensus sits meaningfully above neutral. The mean price target of CHF 154.95 implies roughly 36% upside from current levels, though with no recent changes filed, that target reflects existing views rather than fresh conviction. The dividend score at the 89th percentile underscores Novartis's income appeal, with a forward yield near 3.1%. Valuation multiples have compressed: the P/E has contracted by 1.3 points over the past 30 days to 15.9x, and the price-to-book has shed nearly 0.7 turns to 5.7x — both moving with the stock's decline. The RSI at 38.4 is approaching oversold territory. EV/EBITDA at 12.4x has also drifted lower, consistent with a stock losing price ground against relatively stable earnings estimates.
Among peers, the week has been broadly difficult for large-cap pharma. AZN fell 4.6% on the week and GSK dropped a sharper 7.9%, both tracking macro pressure on defensives. Spinoff SDZ — Sandoz — moved in the opposite direction, up nearly 5%, highlighting divergent sector dynamics even within the Swiss pharma complex.
Q1 results landed on 28 April, triggering a modest negative reaction: the stock slipped 0.65% on the day and remained slightly lower five sessions later. The next earnings event is pencilled for 21 July. Between now and then, the question is whether the insider selling pattern moderates, or whether the Street's 37% upside gap to current prices starts attracting fresh buyers to close the distance.
See the live data behind this article on ORTEX.
Open NOVN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
